# SB Life Science

> SB Life Science is a VC fund in Redwood City backing Health Care and Biotechnology. See 5 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Redwood City, United States
- Total investments: 5
- Last investment: Dec 2021
- Lead investor: 20%
- Last updated: Aug 2026
- X (Twitter): http://twitter.com/ScienceIndex_
- Website: http://www.sblifescience.com

SB Life Science is a VC fund in Redwood City focused on Health Care and Biotechnology. SB Life Science Equity Management is a venture capital firm that is dedicated to funding and building successful businesses in health care. Their team of professionals has experience in venture capital, management consulting and cross-border business development with Asia.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 3 | 60% |
| Biotechnology | 3 | 60% |
| Pharmaceutical | 3 | 60% |
| Medical | 1 | 20% |
| Genetics | 1 | 20% |

6 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series D | 2 | 40% |
| Series C | 1 | 20% |
| Post-IPO Equity | 1 | 20% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| EQRx | EQRx operates as a biotechnology company, focused on re-engineering the process from drug discovery to patient delivery with the goal of offering a market-based solution for the rising cost of medicines.By bringing together stakeholders from across the healthcare system and utilizing the latest advances in science and technology, the companyseeks to discover, develop and deliver high-quality, patent-protected medicines more efficiently and cost-effectively than ever before.The company was founded in 2019 and is based in Cambridge, Massachusetts, United States. | $1.2B | Post-IPO Equity | Dec 17, 2021 |  |
| Perlegen Sciences | Perlegen Sciences engages in the discovery and commercialization of genetic variations that provide physicians with information to improve the clinical decision-making process and patient treatment outcomes. Its products include MammaPLUS, a breast cancer risk stratifier and a panel of common genetic variants that stratifies individual genetic andbackground/clinical risk for those at moderately elevated risk for non-familial breast cancer, as well as impacts the risk for developing invasive breast cancer; and Genotype Browser Website that provides a way to access and view the results of a study of genetic variation in various diverse human populations. Perlegen Sciences, Inc. was founded in 2000 and is based in Mountain View, California. | $50M | Series D | Jan 06, 2006 |  |
| Optimer Pharmaceuticals | Optimer Pharmaceuticals, Inc. (Optimer) is a biopharmaceutical company focused on discovering, developing and commercializing anti-infective products. It has two late-stage anti-infective product candidates, fidaxomicin and Pruvel (prulifloxacin). Optimer's development efforts are focused on products that treat gastrointestinal infections, andrelated diseases where therapies have limitations. Its product portfolio includes Fidaxomicin, Pruvel, CEM-101, OPT-822/OPT-821 Combination Therapy and OPT-88. | $22.2M | Series D | Dec 14, 2005 |  |
| Perlegen Sciences | Perlegen Sciences engages in the discovery and commercialization of genetic variations that provide physicians with information to improve the clinical decision-making process and patient treatment outcomes. Its products include MammaPLUS, a breast cancer risk stratifier and a panel of common genetic variants that stratifies individual genetic andbackground/clinical risk for those at moderately elevated risk for non-familial breast cancer, as well as impacts the risk for developing invasive breast cancer; and Genotype Browser Website that provides a way to access and view the results of a study of genetic variation in various diverse human populations. Perlegen Sciences, Inc. was founded in 2000 and is based in Mountain View, California. | $74M | Series D | Feb 28, 2005 |  |
| Perlegen Sciences | Perlegen Sciences engages in the discovery and commercialization of genetic variations that provide physicians with information to improve the clinical decision-making process and patient treatment outcomes. Its products include MammaPLUS, a breast cancer risk stratifier and a panel of common genetic variants that stratifies individual genetic andbackground/clinical risk for those at moderately elevated risk for non-familial breast cancer, as well as impacts the risk for developing invasive breast cancer; and Genotype Browser Website that provides a way to access and view the results of a study of genetic variation in various diverse human populations. Perlegen Sciences, Inc. was founded in 2000 and is based in Mountain View, California. | $30M | Series C | Jan 28, 2003 |  |

5 of 5 investments shown.

## Co-investors
- [Maverick Ventures](https://shizune.co/investors/profile/maverick-ventures) — VC Fund, 3 deals together
- [Unilever Ventures](https://shizune.co/investors/profile/unilever-ventures) — VC Fund, 3 deals together
- [Brookside Capital](https://shizune.co/investors/profile/brookside-capital) — VC Fund, 2 deals together
- [Casdin Capital](https://shizune.co/investors/profile/casdin-capital) — VC Fund, 2 deals together
- [CMEA Capital](https://shizune.co/investors/profile/cmea-capital) — VC Fund, 2 deals together
- [CSK Venture Capital](https://shizune.co/investors/profile/csk-venture-capital) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Sigma Partners](https://shizune.co/investors/profile/sigma-partners) — VC Fund
- [EDBI](https://shizune.co/investors/profile/edbi) — VC Fund
- [Trifecta Capital Advisors](https://shizune.co/investors/profile/trifecta-capital-advisors) — VC Fund

## FAQ

### What does SB Life Science invest in?

SB Life Science invests primarily in Health Care, Biotechnology and Pharmaceutical startups, most often at Series D and Series C stage. Most of the 5 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did SB Life Science last invest?

The most recent investment recorded for SB Life Science closed in Dec 2021. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co